NRIX
Neutral signalScored 2026-10-19 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Nurix Therapeutics, Inc.
- Nom
- Nurix Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $2.8B
- Employés
- 317
- PDG
- Arthur T. Sands
- Site web
- https://www.nurixtx.com
- Marché
- CCCCKURAKYMRRIGLRVMDSNDX
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 22 583 titres (~528 528,02 $ US)
- Insiders
- GREGORY JULIA P
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$1,621,772
Avg sell (VWAP, 90d window) $23.59 vs last close $26.10 (+10.6%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$846,812 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-14
- Liquidity
- Liquid $61,975,280/day · 20d vol
- Last synced
-
2026-10-20 21:10:53
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-15 | Hansen Gwenn | Sell · S · 10b5-1 | 1,452 | $25.00 | $36,300 | Form 4 |
| 2026-10-14 | GREGORY JULIA P | Sell · S | 22,583 | $23.40 | $528,528 | Form 4 |
| 2026-10-02 | Ring Christine | Sell · S · 10b5-1 | 5,786 | $23.19 | $134,149 | Form 4 |
| 2026-09-02 | Ring Christine | Sell · S · 10b5-1 | 400 | $26.64 | $10,655 | Form 4 |
| 2026-09-01 | Hansen Gwenn | Sell · S · 10b5-1 | 1,452 | $25.47 | $36,982 | Form 4 |
| 2026-08-05 | Hansen Gwenn | Sell · S · 10b5-1 | 4,356 | $25.00 | $108,900 | Form 4 |
| 2026-08-04 | Hansen Gwenn | Sell · S · 10b5-1 | 2,611 | $24.64 | $64,339 | Form 4 |
| 2026-08-04 | van Houte Hans | Sell · S · 10b5-1 | 2,967 | $24.65 | $73,129 | Form 4 |
| 2026-08-03 | Ring Christine | Sell · S · 10b5-1 | 16,589 | $23.05 | $382,358 | Form 4 |
| 2026-07-30 | Hansen Gwenn | Sell · S | 3,847 | $23.38 | $89,954 | Form 4 |
| 2026-07-30 | Ring Christine | Sell · S | 3,847 | $23.38 | $89,954 | Form 4 |
| 2026-07-30 | van Houte Hans | Sell · S | 2,845 | $23.38 | $66,524 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-19 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
NRIX combines a strong liquidity position (score 85) and a meaningful event-driven catalyst (score 75) anchored by a significant Q3 2026 earnings beat and Phase 3 DAYBreak trial initiation with Pfizer/Gilead milestones…
The first sentence of the analysis written for NRIX on 2026-10-19 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 7.02 · operating margin -340% — readings disagree
Suggested stop 20.61, nearest stored support minus 0.5 ATR(21.0% under the last close). Research, not advice. Not an order.
Recent news
- 2026-10-14 Nurix: Maintaining ''Strong Buy'' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways Nurix Therapeutics is maintained at "Strong Buy" due to pivotal progress with bexobrutideg, robust partnerships, and strong financials. The company initiated the phase 3 DAYBreak CLL-306 study, aiming to demonstrate bexobrutideg''s superiority over JAYPIRCA in relapsed/refractory CLL/SLL. Potential Accelerated Approval for bexobrutideg in 3rd-line+ r/r CLL/SLL is supported by promising phase 1/2 data and ongoing pivotal trials.
- 2026-10-12 Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates Nurix Therapeutics, Inc. (NRIX) came out with quarterly earnings of $4.73 per share, beating the Zacks Consensus Estimate of a loss of $0.56 per share. This compares to a loss of $1.03 per share a year ago.
- 2026-10-12 Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL
- 2026-10-07 Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation of bexobrutideg given in combination with venetoclax and selected antibodies in the Roche portfolio of B-cell malignancy therapies BRISBANE, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced that the first patient has been enrolled in the Phase 1b/2 NX-5948-203 study evaluating bexobrutideg, an investigational oral Bruton''s tyrosine kinase (BTK) degrader, in combination with venetoclax, a standard-of-care therapy for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
- 2026-10-05 Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences Two-year extension builds on productive relationship established in 2019 Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Nurix and Gilead Sciences have agreed to extend the research term for an undisclosed oncology program within the companies'' ongoing strategic collaboration by an additional two years.
- 2026-09-29 Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer BRISBANE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the achievement of a $7 million research milestone under its strategic collaboration with Pfizer for the discovery and development of degrader antibody conjugates (DACs).
- 2026-09-25 842,089 Shares in Nurix Therapeutics, Inc. $NRIX Bought by Bank of America Corp DE Bank of America Corp DE acquired a new stake in shares of Nurix Therapeutics, Inc. (NASDAQ: NRIX) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 842,089 shares of the company''s stock, valued at approximately $20,429,000. Bank of America
- 2026-09-17 Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
- 2026-09-16 Nurix Therapeutics, Inc. (NRIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Nurix Therapeutics, Inc. (NRIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-10 Here''s Why You Should Add NRIX Stock to Your Portfolio Now Nurix is developing bexobrutideg in CLL, while Roche''s $2.3B deal and new studies support its potential in cancer, immunology and neurology.
Market snapshot
Financial ratios
| Metric | Trend | 2025-11-30 | 2024-11-30 | 2023-11-30 | 2022-11-30 | 2021-11-30 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 77.5% | -306.3% | -145.7% | -377.6% | -291.4% | |
| Ebit Margin | -314.0% | -354.4% | -187.0% | -466.9% | -393.5% | |
| Ebitda Margin | -291.5% | -324.2% | -169.2% | -438.9% | -373.0% | |
| Operating Profit Margin | -340.2% | -390.5% | -201.4% | -476.0% | -396.3% | |
| Pretax Profit Margin | -314.0% | -354.4% | -187.0% | -466.9% | -393.5% | |
| Continuous Operations Profit Margin | -314.9% | -354.9% | -187.0% | -466.9% | -393.9% | |
| Net Profit Margin | -314.9% | -354.9% | -187.0% | -466.9% | -393.9% | |
| Bottom Line Profit Margin | -314.9% | -354.9% | -187.0% | -466.9% | -393.9% | |
| Current Ratio | 7.018 | 6.462 | 3.398 | 4.507 | 4.696 | |
| Quick Ratio | 7.018 | 6.462 | 3.398 | 4.523 | 4.696 | |
| Solvency Ratio | -1.644 | -1.244 | -0.840 | -1.500 | -0.826 | |
| Cash Ratio | 2.856 | 1.148 | 0.628 | 0.913 | 1.215 | |
| Price To Earnings Ratio | -5.544 | -7.677 | -2.347 | -3.340 | -10.557 | |
| Price To Earnings Growth Ratio | -0.939 | -0.885 | 0.082 | -0.093 | 9.712 | |
| Forward Price To Earnings Growth Ratio | -0.939 | -0.885 | 0.082 | -0.093 | 9.712 | |
| Price To Earnings Diluted Ratio | -5.544 | -7.677 | -2.347 | -3.340 | -10.557 | |
| Price To Earnings Diluted Growth Ratio | -0.939 | -0.885 | 0.082 | -0.093 | 9.712 | |
| Price To Book Ratio | 2.720 | 2.816 | 1.686 | 1.983 | 3.612 | |
| Price To Sales Ratio | 17.451 | 27.205 | 4.390 | 15.592 | 41.554 | |
| Price To Free Cash Flow Ratio | -5.563 | -8.160 | -3.765 | -3.500 | -13.732 | |
| Price To Operating Cash Flow Ratio | -5.875 | -8.599 | -4.154 | -3.769 | -14.654 | |
| Debt To Assets Ratio | 0.081 | 0.042 | 0.086 | 0.029 | 0.027 | |
| Debt To Equity Ratio | 0.103 | 0.054 | 0.153 | 0.039 | 0.038 | |
| Debt To Capital Ratio | 0.094 | 0.051 | 0.132 | 0.038 | 0.037 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.277 | 1.270 | 1.774 | 1.372 | 1.393 | |
| Working Capital Turnover Ratio | 0.161 | 0.149 | 0.337 | 0.157 | 0.119 | |
| Operating Cash Flow Ratio | -2.885 | -1.800 | -0.936 | -2.262 | -1.273 | |
| Operating Cash Flow Sales Ratio | -2.971 | -3.164 | -1.057 | -4.137 | -2.836 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.056 | 1.054 | 1.103 | 1.077 | 1.067 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | -17.398 | -30.660 | -28.883 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | -10.865 | -28.898 | -21.930 | |
| Operating Cash Flow Coverage Ratio | -4.476 | -6.098 | -2.658 | -13.357 | -6.472 | |
| Capital Expenditure Coverage Ratio | -17.816 | -18.611 | -9.685 | -13.052 | -14.903 | |
| Dividend Paid And Capex Coverage Ratio | -17.816 | -18.611 | -9.685 | -13.052 | -14.903 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -5.205 | -7.929 | -2.410 | -3.242 | -10.531 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 77.5% | ▲383.8% | ▲286.2% |
| Ebit Margin | -314.0% | ▲40.4% | ▲29.1% |
| Ebitda Margin | -291.6% | ▲32.7% | ▲27.9% |
| Operating Profit Margin | -340.2% | ▲50.4% | ▲20.7% |
| Pretax Profit Margin | -314.0% | ▲40.4% | ▲29.1% |
| Continuous Operations Profit Margin | -314.9% | ▲40.0% | ▲28.6% |
| Net Profit Margin | -314.9% | ▲40.0% | ▲28.6% |
| Bottom Line Profit Margin | -314.9% | ▲40.0% | ▲28.6% |
| Current Ratio | 7.018 | ▲0.556 | ▲1.802 |
| Quick Ratio | 7.018 | ▲0.556 | ▲1.798 |
| Solvency Ratio | -1.644 | ▼-0.400 | ▼-0.433 |
| Cash Ratio | 2.856 | ▲1.708 | ▲1.504 |
| Price To Earnings Ratio | -5.544 | ▲2.133 | ▲0.349 |
| Price To Earnings Growth Ratio | -0.939 | ▼-0.055 | ▼-2.515 |
| Forward Price To Earnings Growth Ratio | -0.939 | ▼-0.055 | ▼-2.515 |
| Price To Earnings Diluted Ratio | -5.544 | ▲2.133 | ▲0.349 |
| Price To Earnings Diluted Growth Ratio | -0.939 | ▼-0.055 | ▼-2.515 |
| Price To Book Ratio | 2.720 | ▼-0.096 | ▲0.157 |
| Price To Sales Ratio | 17.451 | ▼-9.754 | ▼-3.788 |
| Price To Free Cash Flow Ratio | -5.562 | ▲2.598 | ▲1.382 |
| Price To Operating Cash Flow Ratio | -5.875 | ▲2.724 | ▲1.535 |
| Debt To Assets Ratio | 0.081 | ▲0.039 | ▲0.028 |
| Debt To Equity Ratio | 0.103 | ▲0.050 | ▲0.026 |
| Debt To Capital Ratio | 0.094 | ▲0.043 | ▲0.023 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.277 | ▲0.007 | ▼-0.140 |
| Working Capital Turnover Ratio | 0.161 | ▲0.012 | ▼-0.024 |
| Operating Cash Flow Ratio | -2.885 | ▼-1.085 | ▼-1.054 |
| Operating Cash Flow Sales Ratio | -2.970 | ▲0.193 | ▼-0.138 |
| Free Cash Flow Operating Cash Flow Ratio | 1.056 | ▲0.002 | ▼-0.015 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲15.388 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲12.339 |
| Operating Cash Flow Coverage Ratio | -4.476 | ▲1.621 | ▲2.136 |
| Capital Expenditure Coverage Ratio | -17.816 | ▲0.795 | ▼-3.003 |
| Dividend Paid And Capex Coverage Ratio | -17.816 | ▲0.795 | ▼-3.003 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -5.205 | ▲2.724 | ▲0.659 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.47B | $1.48B | $338.0M | $602.3M | $1.24B | |
| Enterprise value | $1.27B | $1.40B | $314.0M | $549.7M | $1.17B | |
| EV / Sales | 15.17x | 25.71x | 4.08x | 14.23x | 39.29x | |
| EV / Op. cash flow | -5.11x | -8.13x | -3.86x | -3.44x | -13.85x | |
| EV / Free cash flow | -4.84x | -7.71x | -3.50x | -3.19x | -12.98x | |
| EV / EBITDA | -5.21x | -7.93x | -2.41x | -3.24x | -10.53x | |
| Net debt / EBITDA | 0.78x | 0.46x | 0.18x | 0.31x | 0.61x | |
| Current ratio | 7.02x | 6.46x | 3.40x | 4.51x | 4.70x | |
| Income quality | 0.94x | 0.89x | 0.56x | 0.89x | 0.72x | |
| Graham net-net | $5 | $7 | $2 | $4 | $4 | |
| Tax burden | 100.3% | 100.1% | 100.0% | 100.0% | 100.1% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $520.3M | $523.5M | $208.5M | $247.8M | $244.9M | |
| Invested capital | $593.4M | $569.4M | $256.5M | $277.3M | $270.2M | |
| Return on assets | -38.4% | -28.9% | -40.5% | -43.3% | -24.6% | |
| Operating ROA | -42.1% | -41.6% | -40.2% | -41.2% | -27.0% | |
| Return on tangible assets | -38.4% | -28.9% | -40.5% | -43.3% | -24.6% | |
| Return on equity | -49.1% | -36.7% | -71.8% | -59.4% | -34.2% | |
| Return on invested capital | -47.3% | -36.6% | -56.2% | -52.3% | -28.5% | |
| Return on capital employed | -47.5% | -37.1% | -57.7% | -53.1% | -28.7% | |
| Earnings yield | -18.0% | -13.0% | -42.6% | -29.9% | -9.5% | |
| Free cash flow yield | -18.0% | -12.3% | -26.6% | -28.6% | -7.3% | |
| Capex / Op. cash flow | -5.6% | -5.4% | -10.3% | -7.7% | -6.7% | |
| Capex / Depreciation | 74.3% | 56.4% | 61.5% | 113.3% | 93.1% | |
| Capex / Sales | 16.7% | 17.0% | 10.9% | 31.7% | 19.0% | |
| SG&A / Sales | 62.8% | 84.2% | 55.7% | 98.4% | 104.9% | |
| R&D / Sales | 366.9% | 406.3% | 245.7% | 477.6% | 391.4% | |
| Stock comp / Sales | 45.2% | 62.2% | 43.7% | 72.8% | 53.1% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 10d | 4d | 10d | 76d | |
| Days payables outstanding | 217d | 19d | 12d | 10d | 21d | |
| Operating cycle | 0d | 10d | 4d | 8d | 76d | |
| Cash conversion cycle | -217d | -9d | -9d | -2d | 55d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years